• 제목/요약/키워드: .Antitumor activity

검색결과 1,046건 처리시간 0.027초

Design. Synthesis and Antitumor Evaluation of Terpyridine Derivatives Containing Pyridines at 4'- Position

  • Lim, Hyun-Tae;Moon, Yoon-Soo;Zhao, Longxuan;Kim, Eun-Kyung;Kim, Tae-Hyung;Lee, Eung-Seok
    • 대한약학회:학술대회논문집
    • /
    • 대한약학회 2002년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2
    • /
    • pp.347.3-347.3
    • /
    • 2002
  • Recent study indicated that terpyridine and its derivatives displayed highly active antitumor properties. In this presentation. derivatives of terpyridines having three pyridine moieties at 2',4',6'-position of central pyridine skeleton were prepared, and evaluated their cytotoxicity against several human cancer cell lines and topoisomerase I inhibitory activities. Most of the prepared compounds showed strong cytotoxicity compared to doxorubicln. In addition. several compounds displayed better cytotoxicity than that of doxorubicin. In addition, several compounds displayed better cytotoxicity than that of doxorubicin. Structure-activity relationship study was perfomed to be indicated that [2.2':6',2']terpyidine skeleton is important to show strong xytotoxicity. Significant topoxicity. Significant topoisomerase I inhibitory activity was not observed for prepared compounds.

  • PDF

한국산 도꼬마리 추출물로부터 항균.항암물질의 탐색 (Screening of the Antimicrobial and Antitumor Activity of Xanthium strumarium L.Extract)

  • 김현수;유대식;이인선;김용원;여수환
    • KSBB Journal
    • /
    • 제18권1호
    • /
    • pp.55-61
    • /
    • 2003
  • 항균 및 항암성 물질을 탐색하기 위하여 도꼬마리 열수 추출액을 ether 및 ethylacetate를 이용하여 중성, 산성, 염기성조건에서 추출한 후, 각각의 추출물을 세균 16균주 및 곰팡이와 효모 2균주를 대상으로 항균활성을 조사하였다. Ether 중성 추출물(XE-N)은 항균효과가 가장 우수하였으며, 특히 그람 양성세균(7균주), 그람 음성세균(7균주)을 비롯하여 진균중 Cryptococcus neoformans에도 뚜렷한 항균효과를 나타내었다. XE-N 및 XEA-N을 대상으로 FDA method에 의한 항균효과를 검토한 결과, p. aeruginosa를 제외한 3균주에 대해 30 ng/mL에서도 저해효과를 나타내었다 XE-N으로부터 XE-N-S1, XE-N-S3을, Ether 산성 추출물(XE-A)로부터 XE-N-S3 을, ethylacetate 중성 추출물(XEA-N)로부터 XEA-N-S2를 항균, 항암성 물질로 정제하였으나, XE-N-S1을 제외한 다른 물질들은 빠른 시간 내에 모두 분해되었다 도꼬마리 추출물 및 정제된 생리활성물질에 대한 항암효과를 검토한 결과, HeLa 자궁암 세포에 대해서는 XE-N-S1이 가장 우수하였다. HepG2간암세포에 대한 항암효과는 XE-N-S, XE-N-S3가 우수하였고, HT29 대장암세포에 대한 항암효과는 XE-N, XE-N-S1이 우수하였다. Saos2 골육종 암세포, NCI H522 폐선 암세포, NCI H1703 폐 편평세포 암세포와 Clone M3 흑색종 암세포에 대한 항암효과는 XE-N-S1이 가장 우수하였다. LN CAP 전립선 암세포에 대한 항암효과는 XE-N-S3가 가장 우수한 효과를 나타내었다. 또한 HSF 인간 정상 피부 섬유아세포에 대한 각종 추출물 및 정제물의 세포독성을 기존의 항암제인 etoposide와 cisplatin과 비교·검토한 결과, XE-A, XEA-A 및 XEA-B가 가장 독성이 낮았으며, XE-B도 etoposide에 비해 독성이 낮았다. 한편 XE-N-S1, XE-N-S3은 etoposide보다 높은 독성을 나타내었으며, XE-A-S3은 etoposide보다는 독성이 높았으나, cisplatin보다는 낮았다.

Ganoderma lucidum IY 009로 부터 분리된 항암성 다당류의 정제 및 구조분석 (Purification and Structural Analysis of Antitumor Polysaccharides Obtained from Ganoderma lucidum IY 009)

  • 이권행;정훈;이준우;한만덕;최경숙;오두환
    • 한국미생물·생명공학회지
    • /
    • 제22권2호
    • /
    • pp.190-196
    • /
    • 1994
  • Alkali soluble(AS) fraction, revealed the highest antitumor activity of the alkali extracted fractions of G. lucidum IY 009, was loaded on DEAE cellulose(OH$^{-}$ form) column. AS-1, AS-2, AS-3, AS-4 and AS-5 were obtained by stepwise elution with H$_{2}$O, 0.1 M NaHCO$_{3}$, 0.3 M NaHCO$_{3}$, 0.5 M NaHCO$_{3}$ and 0.5 N NaOH respectively, and their antitumor activities(I.R. %) against the sarcoma 180 were 97.5%, 68.0%, 73.0%, 81.0% and 66.0% respectively. AS-1 observed highest antitumor activity was appeared as single peak on the Sepharose CL-4B column chromatography, and their molecular weight was about 580,000 dalton. The carbohydrate content of AS-1 was 98.9%, their monosaccharide consisted of 67.5% of mannose, 22.5% of xylose, 5.8% of glucose, 1.8% of galactose and 2.0% of ribose. AS-1 was assumed $\alpha $linkaged xylomannan having infrared absorption at 864.3 cm$^{-1}$. The main alditol acetates of AS-1 were identified as 1,5-Di-O-acetyl1-2,3,4-Tri-O-methylxylitol, 1,4,5-Tro-O-acety1-2,3,6-Tri-O-methylmannitol and 1,3,4,5-Tetra-O-acety1-2,6-Di-O-methylmannitol by methylation analysis, and their molar ratio was 1 : 2 : 1. The core portion of AS-1 might be $\alpha $-(1$\longrightarrow $ 4)mannopyranosyl unit branched with side chain, C1 of xylopyranosyl residue linked to C3 of every 3 mannopyranosyl units, and the degree of polymerization of structural unit in AS-1 was about 835.

  • PDF

Antitumor Activity of LB42907, a Potent and Selective Farnesyltransferase Inhibitor: Synergistic Effect in Combination with Other Anticancer Drugs

  • Park, Ji-Hyun;Koo, Sun-Young;Kim, Dong-Myung;Kim, Kwi-Hwa;Jeong, Shin-Wu;Chung, Hyun-Ho;Cho, Heung-Soo;Park, Joong-Hoon;Yim, Hyeon-Joo;Lee, Jin-Ho;Koh, Jong-Sung;Kim, Se-Mi
    • Bulletin of the Korean Chemical Society
    • /
    • 제29권7호
    • /
    • pp.1303-1310
    • /
    • 2008
  • Inhibitors of farnesyltransferase (FT), a key enzyme in the post-translational modifications of Ras proteins, have been extensively studied as novel anticancer agents in the preclinical stages, some of which are currently in clinical development. Previously, it has been reported that a novel FT inhibitor LB42907 inhibits Ras farnesylation in the nanomolar range in vitro. The aim of this study was to assess the antitumor efficacy of LB42907 in vitro and in vivo. Anchorage-independent growth of various human tumor cell lines was potently inhibited by treatment with LB42907, comparable to other FT inhibitors in clinical development. In the nude mouse, oral administration of LB42907 demonstrated potent antitumor activity in several human tumor xenograft models including bladder, lung and pancreas origin. Interestingly, significant tumor regression in EJ (bladder) and A549 (lung) xenografts was induced by LB42907 treatment. The effectiveness of LB42907 was also investigated in simultaneous combination with paclitaxel, vincristine, cisplatin or gemcitabine against NCI-H460, A549, and HCT116 cells in vitro using median-effect analysis. LB42907 markedly synergized with most anticancer drugs tested in this study in NCI-H460 cell. In contrast, LB42907 displayed antagonism or partial synergism with these drugs in A549 and HCT116 cells, depending on the class of combined drugs and/ or the level of cytotoxicity. Our results demonstrate that LB42907 is an effective antitumor agent in vitro and in vivo and combination of LB42907 with other chemotherapeutic drugs results in synergistic or antagonistic effects mainly in a cell line-dependent manner. Further preclinical study is warranted.

Antitumor Activity of 7-[2-(N-Isopropylamino)ethyl]-(20s)-camptothecin, CKD602, as a Potent DNA Topoisomerase I Inhibitor

  • Lee, Jun-Hee;Lee, Ju-Mong;Kim, Joon-Kyum;Ahn, Soon-Kil;Lee, Sang-Joon;Kim, Mie-Young;Jew, Sang-Sup;Park, Jae-Gab;Hong, Chung-Il
    • Archives of Pharmacal Research
    • /
    • 제21권5호
    • /
    • pp.581-590
    • /
    • 1998
  • We developed a novel water-soluble camptothecin analobue, CKD602, and evaluated the inhibition of topoisomerase I and the antitumor activities against mammalian tumor cells and human tumor xenografts. CKD602 was a nanomolar inhibitor of the topoisomerase I enzyme in the cleavable complex assay. CKD602 was found to be 3 times and slightly more potent than topotecan and camptothecin as inhibitors of topoisomerase, respecitively. In tumor cell cytotoxicity, CKD602 was more potent than topotecan in 14 out of 26 human cancer cell lines tested, while it was comparable to camptothecin. CKD602 was tested for the in vivo antitumor activity against the human tumor xenograft models. CKD602 was able to imduce regression of established HT-29, WIDR and CX-1 colon tumors, LX-1 lung tumor, MX-1 breast tumor and SKOV-3 ovarian tumor as much as 80, 94, 76, 67, 87% and 88%, respectively, with comparable body weight changes to those of topotecan. Also the therapeutic margin (R/Emax: maximum tolerance dose/$ED-{58}$) of CKD602 was significantly higher than that of topotecan by 4 times. Efficacy was determined at the maximal tolerated dose levels using schedule dependent i.p. administration in mice bearing L1210 leukemia. On a Q4dx4 (every 4 day for 4 doses) schedule, the maximum tolerated dose (MTD) was 25 mg/kg per administration, which caused great weight loss and lethality in <5% tumor bearing mouse. this schedule brought significant increase in life span (ILS), 212%, with 33% of long-term survivals. The ex vivo antitumor activity of CKD602 was compared with that of topotecan and the mean antitumor index (ATI) values recorded for CKD602 were significantly higher than that noted for topotecan. From these results, CKD602 warrants further clinical investigations as a potent inhibitor of topoisomerase I.

  • PDF